Tom 8, Nr 2 (2023)
Artykuł przeglądowy
Opublikowany online: 2023-10-05
Wyświetlenia strony
437
Wyświetlenia/pobrania artykułu
61
Zakażenie SARS-CoV-2 w okresie ciąży
1, 1
Ginekologia i Perinatologia Praktyczna 2023;8(2):74-80.
Streszczenie
Choroba koronawirusowa 2019 (COVID-19) to ostra choroba zakaźna wywołana koronawirusem zespołu ostrej niewydolności
oddechowej 2 (SARS-CoV-2). Kobiety w ciąży są bardziej narażone na ciężki przebieg choroby i śmierć
w przebiegu COVID-19 niż kobiety niebędące w ciąży: 3-krotnie częściej rozwija się niewydolność oddechowa i są
obciążone 1,7-krotnie wyższym ryzykiem zgonu. Zakażenia SARS-CoV-2 w okresie ciąży wiążą się z podwyższonym
ryzykiem wystąpienia stanu przedrzucawkowego, porodu przedwczesnego, urodzenia noworodka z niską
masą oraz zgonu płodu lub noworodka. Ponadto COVID-19 jest czynnikiem ryzyka choroby zakrzepowo-zatorowej
w okresie ciąży. Szczególnie wysokie ryzyko powikłań występuje w ciężkim przebiegu COVID-19. Ryzyko transmisji
wertykalnej wynosi około 3%. Nie stwierdza się więc ochronnego wpływu cięcia cesarskiego na ryzyko zakażenia
noworodka. W leczeniu zaleca się odpowiednie nawodnienie, leki przeciwbólowe i przeciwgorączkowe, stosowanie
nirmatrelwiru z ritonawirem, remdesiwiru, a w przypadku ciężkiego przebiegu z koniecznością stosowania tlenoterapii
— deksametazonu. W ciąży rekomendowane jest podawanie szczepionek przeciwko SARS-CoV-2 opartych
na technologii mRNA lub wektorowych.
Słowa kluczowe: ciążakoronawirusSARS-CoV-2COVID-19leczenieszczepienia
Referencje
- Jamieson DJ, Rasmussen SA. An update on COVID-19 and pregnancy. Am J Obstet Gynecol. 2022; 226(2): 177–186.
- Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol. 2023; 21(3): 147–161.
- COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html (December 19, 2022).
- Kuczyńska K, Zawilska JB, Badura J, et al. Wirus SARS-CoV-2: pochodzenie, budowa i cykl replikacyjny. Farm Pol. 2021; 77: 143–149.
- V'kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021; 19(3): 155–170.
- Whitaker M, Elliott J, Bodinier B, et al. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat Commun. 2022; 13(1): 6856.
- Kelly JC, Raghuraman N, Carter EB, et al. Preprocedural asymptomatic coronavirus disease 2019 cases in obstetrical and surgical units. Am J Obstet Gynecol. 2021; 224(1): 114–116.
- Galang RR, Newton SM, Woodworth KR, et al. Centers for Disease Control and Prevention COVID-19 Response Pregnancy and Infant Linked Outcomes Team. Risk factors for illness severity among pregnant women with confirmed severe acute respiratory syndrome coronavirus 2 infection-surveillance for Emerging Threats to Mothers and Babies Network, 22 State, Local, and Territorial Health Departments, 29 March 2020-5 March 2021. Clin Infect Dis. 2021; 73(Suppl 1): S17–S23.
- Jamieson DJ, Rasmussen SA. An update on COVID-19 and pregnancy. Am J Obstet Gynecol. 2022; 226(2): 177–186.
- DeSisto CL, Wallace B, Simeone RM, et al. Risk for stillbirth among women with and without COVID-19 at delivery hospitalization — United States, March 2020–September 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(47): 1640–1645.
- Balachandren N, Davies MC, Hall JA, et al. SARS-CoV-2 infection in the first trimester and the risk of early miscarriage: a UK population-based prospective cohort study of 3041 pregnancies conceived during the pandemic. Hum Reprod. 2022; 37(6): 1126–1133.
- Baud D, Greub G, Favre G, et al. Second-trimester miscarriage in a pregnant woman with SARS-CoV-2 infection. JAMA. 2020; 323(21): 2198–2200.
- Prochaska E, Jang M, Burd I. COVID-19 in pregnancy: placental and neonatal involvement. Am J Reprod Immunol. 2020; 84(5): e13306.
- Schwartz DA, Avvad-Portari E, Babál P, et al. Placental tissue destruction and insufficiency from COVID-19 causes stillbirth and neonatal death from hypoxic-ischemic injury. Arch Pathol Lab Med. 2022; 146(6): 660–676.
- Wei SQ, Bilodeau-Bertrand M, Liu S, et al. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ. 2021; 193(16): E540–E548.
- Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022; 377: e069590.
- Fahmi A, Brügger M, Démoulins T, et al. SARS-CoV-2 can infect and propagate in human placenta explants. Cell Rep Med. 2021; 2(12): 100456.
- Malicka E, Szymusik I, Rebizant B, et al. sFlt-1/PlGF ratio is not a good predictor of severe COVID-19 nor of adverse outcome in pregnant women with SARS-CoV-2 infection — a case-control study. Int J Environ Res Public Health. 2022; 19(22).
- Espino-Y-Sosa S, Martinez-Portilla RJ, Torres-Torres J, et al. Novel ratio soluble Fms-like tyrosine kinase-1/angiotensin-II (sFlt-1/ANG-II) in pregnant women Is associated with critical illness in COVID-19. Viruses. 2021; 13(10).
- Nitin P, Nandhakumar R, Vidhya B, et al. COVID-19: Invasion, pathogenesis and possible cure — a review. J Virol Methods. 2022; 300: 114434.
- Cai J, Tang Mi, Gao Yu, et al. Cesarean section or vaginal delivery to prevent possible vertical transmission from a pregnant mother confirmed with COVID-19 to a neonate: a systematic review. Front Med (Lausanne). 2021; 8: 634949.
- Carosso A, Cosma S, Serafini P, et al. How to reduce the potential risk of vertical transmission of SARS-CoV-2 during vaginal delivery? Eur J Obstet Gynecol Reprod Biol. 2020; 250: 246–249.
- Qiu L, Liu X, Xiao M, et al. SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection. Clin Infect Dis. 2020; 71(15): 813–817.
- Walker KF, O'Donoghue K, Grace N, et al. Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis. BJOG. 2020; 127(11): 1324–1336.
- Cai J, Tang Mi, Gao Yu, et al. Cesarean section or vaginal delivery to prevent possible vertical transmission from a pregnant mother confirmed with COVID-19 to a neonate: a systematic review. Front Med (Lausanne). 2021; 8: 634949.
- Martínez-Perez O, Vouga M, Cruz Melguizo S, et al. Association between mode of delivery among pregnant women with COVID-19 and maternal and neonatal outcomes in Spain. JAMA. 2020; 324(3): 296–299.
- Krogstad P, Contreras D, Ng H, et al. No evidence of infectious SARS-CoV-2 in human milk: analysis of a cohort of 110 lactating women. medRxiv. 2021.
- Raschetti R, Vivanti AJ, Vauloup-Fellous C, et al. Synthesis and systematic review of reported neonatal SARS-CoV-2 infections. Nat Commun. 2020; 11(1): 5164.
- Bäuerl C, Randazzo W, Sánchez G, et al. MilkCORONA study team. SARS-CoV-2 RNA and antibody detection in breast milk from a prospective multicentre study in Spain. Arch Dis Child Fetal Neonatal Ed. 2022; 107(2): 216–221.
- Rodrigues C, Baía I, Domingues R, et al. Pregnancy and breastfeeding during COVID-19 pandemic: a systematic review of published pregnancy cases. Front Public Health. 2020; 8: 558144.
- Special considerations during pregnancy and after delivery. https://www.covid19treatmentguidelines.nih.gov/special-populations/pregnancy/ (December 19, 2022).
- Gandhi M, Mwesigwa J, Aweeka F, et al. Prevention of Malaria and HIV disease in Tororo (PROMOTE) study. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr. 2013; 63(5): 578–584.
- Budi DS, Pratama NR, Wafa IA, et al. Remdesivir for pregnancy: a systematic review of antiviral therapy for COVID-19. Heliyon. 2022; 8(1): e08835.
- RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285): 1637–1645.
- Stanowisko PTGiP dotyczące szczepień kobiet ciężarnych przeciwko COVID19. https://www.ptgin.pl/artykul/stanowisko-ptgip-dotyczace-szczepien-kobiet-ciezarnych-przeciwko-covid19 (December 19, 2022).
- Dagan N, Barda N, Biron-Shental T, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med. 2021; 27(10): 1693–1695.
- Shimabukuro TT, Kim SY, Myers TR, et al. CDC v-safe COVID-19 Pregnancy Registry Team. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021; 384(24): 2273–2282.
- Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022. https://www.cdc.gov/mmwr/volumes/71/wr/mm7107e3.htm (February 18, 2022).
